Related Experiment Video

Updated: Jun 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial

F Han1, Y Q Xiang2, X H Wang1

  • 1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 17, 2026
PubMed
Abstract

Insights

Becotatug vedotin offers a new treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) after prior therapies. This drug significantly improved objective response rate and progression-free survival compared to chemotherapy.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Recurrent/metastatic nasopharyngeal carcinoma (NPC) presents limited therapeutic avenues post-chemotherapy and programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor failure.
  • Patients with advanced NPC often face a poor prognosis after exhausting standard treatment options.

Purpose of the Study:

  • To evaluate the efficacy and safety of becotatug vedotin versus chemotherapy in patients with recurrent/metastatic NPC.
  • To compare objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) between treatment arms.

Main Methods:

  • A multicenter, open-label, randomized trial involving 173 patients with heavily pretreated recurrent/metastatic NPC.
  • Participants were randomized 1:1 to receive either becotatug vedotin (anti-EGFR ADC) or standard chemotherapy (capecitabine/docetaxel).
  • Co-primary endpoints included ORR, PFS, and OS, assessed by an independent review committee.

Main Results:

  • Becotatug vedotin demonstrated a significantly higher ORR (30.2% vs 11.5%, P=0.003) compared to chemotherapy.
  • Median PFS was significantly improved with becotatug vedotin (5.82 vs 2.83 months; HR=0.63, P=0.01), indicating a reduced risk of progression or death.
  • Interim overall survival data showed a median OS of 17.08 months for becotatug vedotin versus 11.99 months for chemotherapy (HR=0.73, P=0.15).

Conclusions:

  • Becotatug vedotin significantly enhances ORR and PFS in heavily pretreated, immunotherapy-exposed recurrent/metastatic NPC patients.
  • The anti-EGFR antibody-drug conjugate showed comparable safety to chemotherapy.
  • Encouraging, though immature, overall survival results suggest potential benefit for becotatug vedotin.
Keywords:
antibody-drug conjugateepithelial growth factor receptormetastaticnasopharyngeal carcinomarecurrent

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...